July 11, 2016 08:00 AM Eastern Daylight Time
SUNNYVALE, Calif.–(BUSINESS WIRE)–Pelvalon, a medical device company dedicated to developing innovative solutions for women suffering from loss of bowel control, today announced the appointment of Jonathan R. Ward as Vice President of Sales. Mr. Ward will report directly to Pelvalon’s CEO, Miles Rosen.
“I am thrilled to add a Vice President of Sales with the leadership, sales and category expertise of Jon Ward”
Mr. Ward joins Pelvalon with more than 20 years of sales experience in the medical device industry, including specific category experience with incontinence and female pelvic health products. Most recently, he served as Southeast Area Sales Director, Urology and Pelvic Health, for Boston Scientific Corporation. Prior to Boston Scientific, Mr. Ward spent more than a decade in national and regional sales leadership positions at American Medical Systems. Earlier in his career, he served as a top sales representative for Depuy.
“I am thrilled to add a Vice President of Sales with the leadership, sales and category expertise of Jon Ward,” said Miles Rosen, co-founder and CEO of Pelvalon. “As we prepare to expand the launch of the first-of-its-kind Eclipse System, Jon’s experience in accelerating adoption of new technologies will be extremely valuable. Our strong emphasis on clinical research and development, paired with Jon’s industry relationships and experience in commercialization strategies, will help us meet our goal of helping women with loss of bowel control.”
More than 20 million women in the U.S. suffer from loss of bowel control, sometimes called accidental bowel leakage (ABL) or fecal incontinence (FI). This debilitating condition can be caused by pregnancy, childbirth, nerve or muscle damage in the pelvic region, and gastrointestinal disorders such as irritable bowel syndrome (IBS). Sometimes women will feel a strong urge to have a bowel movement; other times, leakage can occur without warning. Typical first-line treatments include dietary changes, exercise and medications. If the issue persists, patients may need to move on to more invasive and costly treatments, such as surgery, surgical implants, or injections. The Eclipse System provides a new, non-surgical option for these women.
The Eclipse System has recently been made available via a limited commercial rollout in select centers of excellence in Illinois, Michigan, Alabama, California, and North Carolina.
“I have been very encouraged to hear the patient and physician response to the Eclipse System in Pelvalon’s early commercial efforts,” said Ward. “I am thrilled to be able to build on the efforts of the company and current clinical evidence to continue the limited release and, in time, expand access so more patients can return to living their lives to the fullest.”
About the Eclipse System
The Eclipse System is the first vaginal insert designed to provide immediate bowel control. Placed in the same location as a tampon or a diaphragm, the insert contains no hormones or drugs and can be removed at any time. In a clinical trial, among the women who were successfully fit and used the insert for one month, Eclipse was effective in 86% of those women. The most common adverse event was pelvic discomfort, most frequently associated with the fitting process and typically resolved by just removing the insert. At the end of the study, 96% of participants successfully fit with the insert found the Eclipse to be comfortable, and 98% reported that they would recommend it to a friend.1
Headquartered in Sunnyvale, California, privately held Pelvalon aims to improve the lives of women who suffer from bowel control problems. Founded in 2010, Pelvalon’s groundbreaking technology originated from Stanford University’s Biodesign program, a collaboration between the schools of medicine and engineering. For more information, visit www.eclipsesystem.com.
1Richter, HE, Matthews, CA, Muir T, et al. A Vaginal Bowel-Control System for the Treatment of Fecal Incontinence. Obstetrics & Gynecology. 2015; 125(3):540-547.
Nicole Osmer, 650.454.0505